Description

Semaglutide Sublingual Tablets

Semaglutide
CAS Number	910463-68-2
Molar Mass	4113.641 g·mol−1
Chemical Formula	C187H291N45O59
IUPAC Name	18-[[(1R)-4-[2-[2-[2-[2-[2-[2-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-2-methylpropanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-18-oxooctadecanoic acid

Brief Introduction

Semaglutide, a prominent subject of scientific inquiry, stands as a research product designed for rigorous investigation. It is essential to emphasize that Semaglutide is exclusively intended for research purposes, and any inference to human consumption is inappropriate.

Key Characteristics

Semaglutide possesses distinct pharmacological characteristics that make it a compelling focus of research. Researchers are actively exploring its interactions within biological systems to unlock its full potential and implications.

Research Applications

Semaglutide finds application in various research studies, with a particular emphasis on blood glucose regulation, potential implications as a weight loss medication, and its impact on brain cell function. Its versatile characteristics make it a subject of interest in understanding mechanisms that may influence therapeutic approaches.

Research Benefits

Improved Blood Glucose Levels

Research studies indicate a promising role for Semaglutide in the improvement of blood glucose levels. Investigations focus on its impact on glucose metabolism and potential applications in conditions related to glycemic control.

Possible Future Weight Loss Medication

Preliminary findings suggest that Semaglutide may have implications as a potential future weight loss medication. Studies explore its impact on appetite regulation and body weight management, providing insights into novel therapeutic avenues.

Improved Brain Cells Function

Emerging research delves into the potential effects of Semaglutide on brain cell function. Initial studies suggest a link between Semaglutide and improved cognitive outcomes, opening avenues for research in neurobiology.

Summary

In summary, Semaglutide, as a research product, exhibits potential benefits in improving blood glucose levels, exploring its role as a potential weight loss medication, and investigating its impact on brain cell function. Researchers are actively engaged in uncovering the underlying mechanisms that may contribute to therapeutic advancements. It is crucial to reiterate that Semaglutide is exclusively intended for research purposes and should not be considered for human consumption.

Disclaimer

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).

Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.

Upon the finalization of your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer contentment stands as our paramount concern. Should you find any dissatisfaction with the product received, kindly contact us at +14197075450 or email our support team at [email protected].

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.

References

Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017; 128: 40–50. [Read More].

Chidekel Bergmann, N., Davies, M. J., Lingvay, I., & Knop, F. K. (2022). Semaglutide for the treatment of overweight and obesity: A review. Diabetes, Obesity and Metabolism. [Read More].

Zhang Q, Liu C, Shi R, Zhou S, Shan H, Deng L, Chen T, Guo Y, Zhang Z, Yang GY, Wang Y, Tang Y. Blocking C3d⁺/GFAP⁺ A1 Astrocyte Conversion with Semaglutide Attenuates Blood-Brain Barrier Disruption in Mice after Ischemic Stroke. Aging Dis. 2022 Jun 1;13(3):943-959. doi: 10.14336/AD.2021.1029. PMID: 35656116; PMCID: PMC9116904. [Read More].